Lasa Supergenerics Ltd

Lasa Supergenerics Ltd has announced that its Board of Directors will convene on August 14, 2026. The primary agenda items include the consideration and approval of the unaudited financial results for the quarter ended June 30, 2026. Additionally, the board will discuss any other matters with the Chairperson's permission. In line with SEBI regulations, the trading window will remain closed until 48 hours after the declaration of these financial results. The company has also made this information available on its website and the BSE and NSE websites.

Lasa Supergenerics Ltd has announced the closure of its trading window for designated employees and their immediate relatives. This closure is effective from July 01, 2026, and will remain in effect until 48 hours after the declaration of the Unaudited Financial Results for the quarter ended June 30, 2026. This measure is in compliance with the company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, as per SEBI (Prohibition of Insider Trading) Regulations, 2015.

Lasa Supergenerics Ltd has announced its audited financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results on May 29, 2026, following a review by the audit committee. Revenue from operations for the year ended March 31, 2026, stood at ₹2,514.07 Lakhs. The statutory auditors issued an audit report with a modified opinion. A fire incident at the company's factory on May 18, 2025, resulted in significant damage.

Lasa Supergenerics Ltd. disclosed its related party transactions as of March 31, 2026, in compliance with Regulation 23(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. The transactions include remuneration to directors, sitting fees to independent directors, remuneration to the company secretary and CFO, and donations given. The total value of these transactions amounts to ₹35.36.

Lasa Supergenerics Ltd's board approved the audited financial results for the quarter and year ended March 31, 2026. Revenue from operations for the year ended March 31, 2026, stood at ₹2,514.07 lakhs. The company reported a net loss after tax of ₹2,211.66 lakhs. The auditor's report for the quarter ended March 31, 2026, has a modified opinion. A fire incident at the company's factory on May 18, 2025, resulted in significant damage and operational disruption, with uninsured losses recognized as exceptional items.

Lasa Supergenerics Ltd's board approved the unaudited financial results for the quarter ended March 31, 2026. The company reported a loss before tax of ₹397.68 lakhs for the quarter. Revenue from operations stood at ₹(13.15) lakhs. The results were reviewed by the audit committee and approved by the board on May 29, 2026. A fire incident at the company's factory in May 2025 resulted in significant losses, impacting production activities.

Lasa Supergenerics Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026. The trading window remains closed until 48 hours after the declaration of the results, as per SEBI regulations. The information is available on the company's website and stock exchange websites.

Lasa Supergenerics Ltd has officially declared that it does not fall under the 'Large Corporate' category as defined by SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144, dated November 26, 2018. This circular outlines the framework and compliance requirements for fund raising through debt securities by Large Entities. By this declaration, the company confirms it is out of the purview of these specific regulations.

Lasa Supergenerics Ltd has announced the closure of the trading window for designated employees and their immediate relatives. The closure is in accordance with the Company’s Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders. The trading window will be closed from April 01, 2026 till 48 hours after the declaration of Audited Financial Results for the quarter and the year ended March 31, 2026. This announcement was made by Ganesh Suresh Potdar, Director of Lasa Supergenerics Ltd.

Lasa Supergenerics Ltd has announced its unaudited financial results for the quarter ended December 31, 2025. The board of directors considered and approved these results in a meeting held on February 13, 2026. The company does not have any outstanding loans or debt securities as of December 31, 2025.